{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:38:45Z","timestamp":1786523925657,"version":"build-2736575974"},"reference-count":49,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Victor Babes University of Medicine and Pharmacy, Timisoara"},{"id":[{"id":"https:\/\/ror.org\/00afdp487","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Psilocybin-assisted therapy has progressed from early proof-of-concept work to a substantially expanded evidence base, with four pivotal studies published in 2025\u20132026 that were not incorporated into earlier reviews. This review synthesizes the pharmacological and neurobiological foundations of psilocybin and appraises clinical evidence across major depressive disorder (MDD), treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), cancer-related distress, and substance use disorders, emphasizing long-term durability, expanding indications, and methodological limitations. Methods: A narrative review was conducted using a targeted search of PubMed\/MEDLINE, Embase, Scopus, and Web of Science (January 2000\u2013April 2026), emphasizing 2025\u20132026 publications. Predefined eligibility principles prioritized randomized controlled trials, long-term follow-up studies, and systematic reviews; formal PRISMA procedures were not applied, consistent with the narrative design. Results: Four 2025\u20132026 studies extend the evidence base: a 52-week follow-up confirming dose-dependent maintenance of antidepressant benefit after a single 25 mg psilocybin session; the first pilot study in Veterans with severe TRD, reporting a 60% response rate at three weeks; the first safety trial in PTSD, where symptom improvement tracked self-transcendent experience intensity but worsened with session anxiety; and a living review of 15 randomized trials confirming a meaningful antidepressant effect while identifying functional unblinding as a substantial threat to effect estimates. Conclusions: Evidence supports psilocybin-assisted therapy as mechanistically distinct and clinically promising, most strongly in MDD and TRD, with preliminary support in PTSD and Veterans. Functional unblinding, small open-label designs, narrow safety populations, and absent SSRI-integration protocols constrain the current conclusions.<\/jats:p>","DOI":"10.3390\/jcm15166228","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:57:26Z","timestamp":1786521446000},"page":"6228","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025\u20132026)"],"prefix":"10.3390","volume":"15","author":[{"given":"Teodora","family":"Anghel","sequence":"first","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-3714","authenticated-orcid":false,"given":"Adriana","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-3008","authenticated-orcid":false,"given":"Lavinia","family":"Hogea","sequence":"additional","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-3486","authenticated-orcid":false,"given":"Iuliana","family":"Costea","sequence":"additional","affiliation":[{"name":"Psychology Department, West University of Timisoara, 300223 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Marinca","sequence":"additional","affiliation":[{"name":"Center for Studies and Research in Psychology, Faculty of Psychology, \u201cTibiscus\u201d University, Lasc\u0103r Catargiu 4-6, 300559 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-8130","authenticated-orcid":false,"given":"Raluca","family":"Dumache","sequence":"additional","affiliation":[{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2617-0470","authenticated-orcid":false,"given":"Iuliana-Anamaria","family":"Tr\u0103il\u0103","sequence":"additional","affiliation":[{"name":"Ph.D. School, Faculty of Medicine, Department of Microscopic Morphology, Genetics Discipline, Center of Genomic Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_2","unstructured":"Grinspoon, L., and Bakalar, J.B. (1998). Psychodelic Drugs Reconsidered, Lindesmith Center. [2nd ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fiorillo, A., Demyttenaere, K., Martiadis, V., and Martinotti, G. (2025). Editorial: Treatment Resistant Depression (TRD): Epidemiology, Clinic, Burden and Treatment. Front. Psychiatry, 16.","DOI":"10.3389\/fpsyt.2025.1588902"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/00048674241240597","article-title":"A Taxonomy of Regulatory and Policy Matters Relevant to Psychedelic-Assisted Therapy in Australia","volume":"58","author":"Hatfield","year":"2024","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yu, F., Tafur, J., Moreno, F., and Dahmer, S. (2026). Inaugural Year of Regulated Psilocybin Services in Oregon: Safety, Motivations, and Utilization. Front. Psychiatry, 17.","DOI":"10.3389\/fpsyt.2026.1777387"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic Drug Legislative Reform and Legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24m15449","DOI":"10.4088\/JCP.24m15449","article-title":"Results from a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder","volume":"86","author":"Goodwin","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jad.2024.09.133","article-title":"Single-Dose Psilocybin for U.S. Military Veterans with Severe Treatment-Resistant Depression\u2014A First-in-Kind Open-Label Pilot Study","volume":"369","author":"Ellis","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/02698811251362390","article-title":"Investigating the Safety and Tolerability of Single-Dose Psilocybin for Post-Traumatic Stress Disorder: A Nonrandomized Open-Label Clinical Trial","volume":"40","author":"McGowan","year":"2026","journal-title":"J. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1556\/2054.2023.00297","article-title":"Indigenous Psilocybin Mushroom Practices: An Annotated Bibliography","volume":"8","author":"Spiers","year":"2024","journal-title":"J. Psychedelic Stud."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hlca.19590420518","article-title":"Psilocybin Und Psilocin, Zwei Psychotrope Wirkstoffe Aus Mexikanischen Rauschpilzen","volume":"42","author":"Hofmann","year":"1959","journal-title":"Helv. Chim. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Meshkat, S., Al-Shamali, H., Perivolaris, A., Tullu, T., Zeifman, R.J., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A., and Husain, M.I. (2025). Pharmacokinetics of Psilocybin: A Systematic Review. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17040411"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Thomann, J., Kolaczynska, K.E., Stoeckmann, O.V., Rudin, D., Vizeli, P., Hoener, M.C., Pryce, C.R., Vollenweider, F.X., Liechti, M.E., and Duthaler, U. (2024). In Vitro and in Vivo Metabolism of Psilocybin\u2019s Active Metabolite Psilocin. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1391689"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for Treatment Resistant Depression in Patients Taking a Concomitant SSRI Medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/02698811241237870","article-title":"Effects of Discontinuation of Serotonergic Antidepressants Prior to Psilocybin Therapy versus Escitalopram for Major Depression","volume":"38","author":"Erritzoe","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing Drug-Induced QT Prolongation in Clinical Practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100021","DOI":"10.1016\/j.foodw.2025.100021","article-title":"Exploring the Health Benefits, Mechanisms of Action, and Emerging Safety Concerns of Fermented Foods with Emphasis on African Foods","volume":"1","author":"Obayomi","year":"2025","journal-title":"Food Wellness"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing Psilocybin: Antidepressant-like Behavioral and Synaptic Actions of Psilocybin Are Independent of 5-HT2R Activation in Mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics Promote Neuroplasticity through the Activation of Intracellular 5-HT2A Receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/02698811241249436","article-title":"Psilocybin Promotes Neuroplasticity and Induces Rapid and Sustained Antidepressant-like Effects in Mice","volume":"38","author":"Zhao","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamapsychiatry.2015.0071","article-title":"Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-Analysis of Resting-State Functional Connectivity","volume":"72","author":"Kaiser","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/schbul\/sbs117","article-title":"Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis","volume":"39","author":"Leech","year":"2013","journal-title":"Schizophr. Bull."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for Treatment-Resistant Depression: fMRI-Measured Brain Mechanisms","volume":"7","author":"Roseman","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased Global Integration in the Brain after Psilocybin Therapy for Depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an Understanding of Psychedelic-Induced Neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1111\/bph.70138","article-title":"Are We Hallucinating or Can Psychedelic Drugs Modulate the Immune System to Control Inflammation?","volume":"183","author":"Qureshi","year":"2026","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/16066350500053562","article-title":"Reducing the Risks of Drug Use: The Case for Set and Setting","volume":"13","author":"Dalgarno","year":"2005","journal-title":"Addctn. Res. Theory"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/7854_2017_474","article-title":"Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates","volume":"Volume 36","author":"Halberstadt","year":"2017","journal-title":"Behavioral Neurobiology of Psychedelic Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with Life-Threatening Cancer: A Randomized Controlled Trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey Study of Challenging Experiences after Ingesting Psilocybin Mushrooms: Acute and Enduring Positive and Negative Consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113612","DOI":"10.1016\/j.biopha.2022.113612","article-title":"Serotonin 5-HT2A, 5-HT2c and 5-HT1A Receptor Involvement in the Acute Effects of Psilocybin in Mice. In Vitro Pharmacological Profile and Modulation of Thermoregulation and Head-Twich Response","volume":"154","author":"Horrillo","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Giribaldi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0006-3223(03)00566-3","article-title":"Depression and Cancer: Mechanisms and Disease Progression","volume":"54","author":"Spiegel","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-Term Follow-up of Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Patients with Life-Threatening Cancer","volume":"34","author":"Malone","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot Study of the 5-HT2A R Agonist Psilocybin in the Treatment of Tobacco Addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients with Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., and Sergent, F. (2025). Psilocybin in Alcohol Use Disorder and Comorbid Depressive Symptoms: Results from a Feasibility Randomized Clinical Trial. Addiction, Epub ahead of printing.","DOI":"10.1111\/add.70152"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Van Der Meer, P.B., Fuentes, J.J., Kaptein, A.A., Schoones, J.W., De Waal, M.M., Goudriaan, A.E., Kramers, K., Schellekens, A., Somers, M., and Bossong, M.G. (2023). Therapeutic Effect of Psilocybin in Addiction: A Systematic Review. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1134454"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s44220-026-00630-8","article-title":"A Living Systematic Review, Meta-Analysis and Open-Data Resource of Randomized Controlled Trials of Psilocybin Treatment for Symptoms of Depression","volume":"4","author":"Singleton","year":"2026","journal-title":"Nat. Ment. Health"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Jakobsen, J.C., Katakam, K.K., Schou, A., Hellmuth, S.G., Stallknecht, S.E., Leth-M\u00f8ller, K., Iversen, M., Banke, M.B., Petersen, I.J., and Klingenberg, S.L. (2017). Selective Serotonin Reuptake Inhibitors versus Placebo in Patients with Major Depressive Disorder. A Systematic Review with Meta-Analysis and Trial Sequential Analysis. BMC Psychiatry, 17.","DOI":"10.1186\/s12888-016-1173-2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2020.2148","article-title":"Dialectical Behavior Therapy for Posttraumatic Stress Disorder (DBT-PTSD) Compared with Cognitive Processing Therapy (CPT) in Complex Presentations of PTSD in Women Survivors of Childhood Abuse","volume":"77","author":"Bohus","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/00275514.1971.12019202","article-title":"A Minute New Echinostelium with Protostelid Affinities","volume":"63","author":"Olive","year":"1971","journal-title":"Mycologia"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Martiadis, V., Raffone, F., Testa, S., Iaccarino, C., Giunnelli, P., Orrico, A., Carbone, E., Clemente, S., De Simone, C., and Massa, A. (2026). Integrating Psychiatric, Psychotherapeutic, and Nursing Care in Intranasal Esketamine for Treatment-Resistant Depression. J. Clin. Med., 15.","DOI":"10.3390\/jcm15041629"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6228\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:21:46Z","timestamp":1786522906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":49,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166228"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166228","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}